1. Home
  2. ATYR vs FSBW Comparison

ATYR vs FSBW Comparison

Compare ATYR & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • FSBW
  • Stock Information
  • Founded
  • ATYR 2005
  • FSBW 1936
  • Country
  • ATYR United States
  • FSBW United States
  • Employees
  • ATYR N/A
  • FSBW N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • FSBW Banks
  • Sector
  • ATYR Health Care
  • FSBW Finance
  • Exchange
  • ATYR Nasdaq
  • FSBW Nasdaq
  • Market Cap
  • ATYR 330.7M
  • FSBW 318.4M
  • IPO Year
  • ATYR 2015
  • FSBW 2012
  • Fundamental
  • Price
  • ATYR $3.91
  • FSBW $36.47
  • Analyst Decision
  • ATYR Strong Buy
  • FSBW Hold
  • Analyst Count
  • ATYR 6
  • FSBW 1
  • Target Price
  • ATYR $18.60
  • FSBW $44.00
  • AVG Volume (30 Days)
  • ATYR 2.0M
  • FSBW 11.8K
  • Earning Date
  • ATYR 03-13-2025
  • FSBW 04-23-2025
  • Dividend Yield
  • ATYR N/A
  • FSBW 2.94%
  • EPS Growth
  • ATYR N/A
  • FSBW N/A
  • EPS
  • ATYR N/A
  • FSBW 4.36
  • Revenue
  • ATYR $235,000.00
  • FSBW $139,150,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • FSBW $9.22
  • Revenue Next Year
  • ATYR $873.22
  • FSBW $6.31
  • P/E Ratio
  • ATYR N/A
  • FSBW $8.43
  • Revenue Growth
  • ATYR N/A
  • FSBW 0.09
  • 52 Week Low
  • ATYR $1.42
  • FSBW $30.64
  • 52 Week High
  • ATYR $4.66
  • FSBW $49.15
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 57.44
  • FSBW 47.22
  • Support Level
  • ATYR $2.98
  • FSBW $36.05
  • Resistance Level
  • ATYR $3.73
  • FSBW $38.01
  • Average True Range (ATR)
  • ATYR 0.40
  • FSBW 0.92
  • MACD
  • ATYR 0.06
  • FSBW 0.02
  • Stochastic Oscillator
  • ATYR 81.06
  • FSBW 57.22

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking, and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

Share on Social Networks: